Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil.

Article Details

Citation

Copy to clipboard

Mazurov AV, Menshikov MYu, Leytin VL, Tkachuk VA, Repin VS

Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil.

FEBS Lett. 1984 Jul 9;172(2):167-71.

PubMed ID

6086387 [ View in PubMed

]

Abstract

Trapidil (N,N-diethyl-5-methyl[1,2,4]triazolo[1,5-alpha]pyrimidine-7-amine ) inhibits platelet spreading and aggregation induced by arachidonic acid (AA), a stable analogue of prostaglandin (PG) endoperoxides (U46619), ADP, and low concentrations of thrombin, but not by A23187 and high concentrations of thrombin. Trapidil does not affect platelet adenylate cyclase but inhibits the cAMP PDE by approx. 50%. PDE inhibition proceeds via a competitive mechanism (Ki = 0.52 mM) and is not mediated by calmodulin inhibition. Trapidil does not change the platelet basal cAMP level but potentiates an increase of cAMP induced by the stable prostacyclin analogue (6 beta-PGI1). These results suggest that trapidil antiplatelet effects may be due to the inhibition of platelet PDE.

DrugBank Data that Cites this Article

Drugs

Trapidil

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Trapidil	Cyclic nucleotide phosphodiesterase (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details